A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Deferasirox In Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) And Transfusional Iron Overload (Telesto).

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Deferasirox In Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) And Transfusional Iron Overload (Telesto).

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Telesto
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 16 Feb 2018 New source identified and integrated (European Clinical Trials Database; EudraCT2009-012418-38).
    • 30 Jun 2012 New source identified and integrated (9L11-2: University of Southern California Norris Comprehensive Cancer Center).
    • 30 Jun 2012 Additional lead trial investigator identified as reported by University of Southern California Norris Comprehensive Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top